Search research articles
Contact Us
Filters
Showing results (161-170 of 185) with videos related to
Page
of 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
H S Rugo, E Tokunaga, H Iwata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2010
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
A-M C Dingemans, A J de Langen, V van den Boogaart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
E F Smit, M A Socinski, B P Mullaney, et al.
Plos One
|
August 31, 2017
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
A J van der Wekken, J L Kuiper, A Saber, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 18, 2014
EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
L E L Hendriks, E F Smit, B A H Vosse, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 4, 2019
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile
B C M Hermans, J L Derks, E Thunnissen, et al.
JTO Clinical and Research Reports
|
April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC
M Jebbink, A J de Langen, K Monkhorst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2013
Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis
N E Verstegen, J W A Oosterhuis, D A Palma, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 20, 2019
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)
B C M Hermans, J L Derks, E Thunnissen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 185) with videos related to
Sort By:
Page
of 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
H S Rugo, E Tokunaga, H Iwata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2010
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
A-M C Dingemans, A J de Langen, V van den Boogaart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
E F Smit, M A Socinski, B P Mullaney, et al.
Plos One
|
August 31, 2017
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
A J van der Wekken, J L Kuiper, A Saber, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 18, 2014
EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
L E L Hendriks, E F Smit, B A H Vosse, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 4, 2019
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile
B C M Hermans, J L Derks, E Thunnissen, et al.
JTO Clinical and Research Reports
|
April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC
M Jebbink, A J de Langen, K Monkhorst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2013
Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis
N E Verstegen, J W A Oosterhuis, D A Palma, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 20, 2019
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)
B C M Hermans, J L Derks, E Thunnissen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
G R Blumenschein, E F Smit, D Planchard, et al.
Page
of 19